Fluoroquinolone-Induced Photosensitivity: A Chemical Fragment-Based Approach by a Case/Non-case Study in VigiBase®

Yoann Zelmat (), Vanessa Rousseau, Leila Chebane, Jean-Louis Montastruc, Haleh Bagheri and Agnès Sommet
Additional contact information
Yoann Zelmat: Centre Hospitalier Universitaire de Toulouse
Vanessa Rousseau: Centre Hospitalier Universitaire de Toulouse
Leila Chebane: Centre Hospitalier Universitaire de Toulouse
Jean-Louis Montastruc: Centre Hospitalier Universitaire de Toulouse
Haleh Bagheri: Centre Hospitalier Universitaire de Toulouse
Agnès Sommet: Centre Hospitalier Universitaire de Toulouse

Drug Safety, 2020, vol. 43, issue 6, No 7, 566 pages

Abstract: Abstract Introduction Fluoroquinolones are widely used to treat bacterial infections. Many in vitro and in vivo studies have established a chemical relationship between fluoroquinolones’ particular chemical structure and photosensitivity. The aim of this study was to establish a relationship between the chemical structure of fluoroquinolones and the risk of photosensitivity adverse effects from real-world data. Methods All the Individual Case Safety Reports (ICSRs) related to fluoroquinolones and registered in the World Health Organization global database (VigiBase®) up to December 31, 2017 were collected. A disproportionality analysis was performed in order to quantify the photosensitivity risk for each fluoroquinolone by calculating their reporting odds ratio (ROR). Results Up to December 31, 2017, 282,805 ICSRs related to fluoroquinolones were selected, of which 1647 were photosensitivity adverse event cases. Sparfloxacin had the highest adjusted ROR of 161.10 (95% confidence interval [CI] 133.66–194.02) followed by grepafloxacin (40.30 [26.30–59.60]) closely followed by lomefloxacin (32.61 [28.61–37.07]), then enoxacin (11.04 [8.33–14.32]) and fleroxacin (8.22 [5.06–12.56]). Conclusion This study confirms the high reporting rate of photosensitivity adverse effects for sparfloxacin from real-world data. Moreover, our data suggest more photosensitivity adverse effects reporting for fluoroquinolones with a halogen at their 8th position.

Date: 2020
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40264-020-00917-4 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:drugsa:v:43:y:2020:i:6:d:10.1007_s40264-020-00917-4

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/40264

DOI: 10.1007/s40264-020-00917-4

Access Statistics for this article

Drug Safety is currently edited by Nitin Joshi

More articles in Drug Safety from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().